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i.org/1risk of thromboembolism and stroke; however, these risks are not the same for women and
men. This review examines the evidence and clinical signiﬁcance of increased thrombo-
embolic risk in women with AF. The balance of results from over 30 recent studies suggests
that female gender is an independent stroke risk factor in AF, and the inclusion of female
gender in stroke risk stratiﬁcation models, such as CHA2DS2-VASc, has improved risk
assessment. Reasons for the increased thrombogenicity in women remain incompletely
elucidated, but biological factors including increased hypertension, renal dysfunction, and
hyperthyroidism in female patients with AF; cardiovascular remodeling; increased hyper-
coagulability, and estrogen hormone replacement therapy in women have been proposed.
More importantly, gender differences exist in medical management of patients with AF, and
compared with men, women have been found to have greater thromboembolic risk when
not on anticoagulants, but may beneﬁt from greater risk reduction when systemically
anticoagulated. In conclusion, increased clinician awareness of these gender differences
may help to improve the management of patients with AF.  2016 The Authors. Pub-
lished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;117:1021e1027)Atrial ﬁbrillation (AF), the most common clinically
relevant arrhythmia, affects 2.7 to 6.1 million Americans,
with prevalence projected to double by the year 2050.1 The
prevalence of AF is 3.2% of the population aged 20 years
and reaches 20% at age 80.2 Men have a greater risk of
developing AF than women by a factor of 1.5 after adjusting
for other risk factors.3 However, the absolute numbers of
men and women with AF are roughly equal because of the
higher average life expectancy of women.4,5 Women make
up about 60% of the population with AF aged >75, the
median age of AF onset.6
AF is associated with a ﬁvefold increased risk of stroke7
and is attributed with at least 50% of strokes occurring in
subjects aged 80 years and older.2 Many risk stratiﬁcation
models have been proposed to quantify the risk of stroke in
AF. The inclusion of female gender as an independent risk
factor has been the subject of recent examination. AF is more
frequently noted in women presenting with stroke than in
men.8 In addition, women have a worse poststroke outcome
than men in terms of motor and cognitive function and ac-
tivities of daily living.9 AF is an independent stroke predictor
of in-hospital mortality for women but is not for men.10
Thus, these gender differences are clinically relevant to
make accurate estimations of inherent stroke risk in patients
with AF. This is important because patients with AF with
the highest stroke risk derive the greatest absolute beneﬁt
from systemic anticoagulation.11 As such, clinicianCardiology, E. Palo Alto, California. Manuscript
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0.1016/j.amjcard.2015.12.040awareness of such gender differences becomes useful when
a decision regarding anticoagulation is needed and few or no
other risk factors exist. Current European Society of
Cardiology (ESC) guidelines recommend that no systemic
anticoagulation is required for female patients aged
<65 years with lone AF (CHA2DS2-VASc ¼ 1) because
these patients are considered low risk for stroke, which
stands in contrast to other subgroups with CHA2DS2-
VASc ¼ 1. The primary objective of this review is to
provide an updated overview of the existing evidence for
gender differences in thromboembolic risk and to discuss
the clinical importance of such differences.
Methods
The PubMed database was used to review the English lan-
guage reports addressing gender differences and thromboem-
bolic risk in AF from 1994 to the present. The search used
combinations of terms including “atrial ﬁbrillation,” “gender
OR sex OR female OR women,” and “thromboembolism OR
stroke.” References of retrieved studies were further reviewed
in detail for additional relevant studies and reviews.
Studies were selected for inclusion if they published stroke
incidence data in men and in women. The number of women,
number of total study participants, mean age of men and
women, percent incidence of stroke in men and women, and
relative risk (RR) for stroke for women were collected from
each study when available. Difference in stroke risk was
evaluated by examining the reported RR values, and if these
were unavailable, by examining the p-value for statistically
signiﬁcant differences in stroke rates betweenmen andwomen.
No extramural funding was used to support this work.
The investigators are solely responsible for the design and
conduct of this study, all study analyses, the drafting, and
editing of the study and its ﬁnal contents.ccess article
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Risk: We compiled over 30 studies published since 1999
that examine gender and thromboembolic risk, including 5
randomized controlled trials (RCTs) and 24 observational
studies (Tables 1 and 2). Of these 30 studies, 17 studies
reported that female gender is a signiﬁcant risk
factor,13e16,19,21,22,25,27,31,33e39 12 studies reported that
female gender is not signiﬁcant,17,18,20,23,24,26,28e30,32,40,41
and only 1 study reported that male gender is a signiﬁcant
risk factor.12 Four additional RCTs compared novel oral
anticoagulant drugs (NOAC) and warfarin, providing further
data on gender differences (Table 3).42e45 However, 1 RCT37
and 1 observational study34 no longer found a signiﬁcant
difference after multivariate analysis. Four studies, all
reporting insigniﬁcant gender differences, only reported
univariate risk estimates associatedwith female gender.18,24,29,32
Although only 13 of the 25 observational studies reported
female gender as signiﬁcant, 2 of the 12 observational studies
that reported no signiﬁcant gender differences had abnormal
age distributions, which may have skewed the data. The
Elderly Patients followed by Italian Centres for Anti-
coagulation (EPICA) study only included patients over
80 years old,13 and a Beijing hospital study reported that the
lack of signiﬁcant gender differences may be because the fe-
male patients were younger and had fewer co-morbidities.19
The Stroke Prevention in Atrial Fibrillation (SPAF) trials
of the 1990s provided early data on gender differences.38
These studies reported that women with AF have a greater
risk of stroke than men (RR 1.6, p ¼ 0.01), and this dif-
ference in stroke rate was substantially greater in patients
aged >75 years. The largest RCT was the Anticoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) study with a
cohort of 13,559 adults with AF.36 This was the ﬁrst RCT
with enough end points to examine the inﬂuence of gender
on stroke risk. The study reported that the annual incidence
rates of thromboembolism off warfarin were 3.5% for
women versus 1.8% for men (RR 1.9, 95% CI 1.6 to 2.4).
The difference between the RR of thromboembolism for
women versus men for those aged 75 years (RR 1.6, 95%
CI 1.0 to 2.3) and those aged >75 years (RR 1.8, 95% CI
1.4 to 2.3) was not statistically different.
Gender as an Independent Stroke Risk Factor:
Interestingly, the balance of evidence suggests that female
gender is an independent thromboembolic risk factor. Several
meta-analyses have also found that women appear to have an
increased stroke risk compared with their male counterparts.
One meta-analysis of 17 studies reported a 1.31-fold (95%
CI 1.18 to 1.46) increased stroke risk in women with AF,
especially those aged 75 years, regardless of oral
anticoagulation (OAC) therapy.46 Another meta-analysis
reported that women with AF have a signiﬁcantly greater
residual risk of cerebrovascular accident/systemic embolism
compared with men with AF (odds ratio 1.279, 95% CI
1.111 to 1.473, p ¼ 0.001) while on warfarin, but there was
no signiﬁcant gender difference in residual risk of
cerebrovascular accident/systemic embolism in patients
with AF on novel OACs (odds ratio 1.146, 95% CI 0.97 to
1.354, p ¼ 0.109).47 A meta-analysis analyzing the warfarin
arm of 6 studies found that women with AF treated with
OAC therapy still had higher stroke rates than men (RR1.30, 95% CI 1.15 to 1.49, p <0.001).48 Likewise, there
have been several systematic reviews of contemporary data
on stroke in women with AF that have found female gender
to be an independent predictor of stroke in AF with reported
average RRs of 1.5 to 1.9.49e51
Comparison of Stroke Risk Stratiﬁcation Models
Regarding Gender: Female gender is increasingly recognized
as a stroke risk factor in AF (Table 4). A previously commonly
used stroke risk stratiﬁcation model, CHADS2 (1 point each for
congestive heart failure, hypertension, age 75 years, and
diabetes mellitus and 2 points for previous stroke/transient
ischemic attack) does not include gender.52 A large Swedish
cohort study found that at each CHADS2 score, the stroke rate
was higher in women than in men.22 In light of the mounting
evidence suggesting increased thromboembolic risk in women
compared with men, the CHA2DS2-VASc (CHA2DS2 and 1
point each for vascular disease, age 65 to 74 years, and gender
category) model was developed to complement CHADS2 by
considering additional stroke risk factors, including female
gender, age 65 to 74, and vascular disease.
Several studies support the use of CHA2DS2-VASc
score, particularly for its additional predictive value for
patients with low CHADS2 scores.
31,53 A Danish cohort
study reported that CHA2DS2-VASc performed better than
CHADS2 in identifying patients at high risk and at truly low
risk.19 Likewise, a Chinese AF cohort study found that the 3
new components of CHA2DS2-VASc, including age 65 to
74 years, female gender, and a history of other vascular
disease, were predictive of stroke in their cohort.34 A study
on postmenopausal women with AF found that for CHADS2
<2, stroke risk almost doubles with each additional
CHA2DS2-VASc point.
54 A Taiwanese study reported that
women with AF with a CHA2DS2-VASc score of 1 (no risk
factors other than gender) had a 2.5-fold stroke risk
compared with men with AF with a score of 0, further
validating the additional point for female gender.21
That women with AF are at higher risk for thromboem-
bolic events has been highlighted by the recognition and
inclusion of female gender as an independent risk factor in
newer stroke risk prediction models. However, although
there are data to suggest that women with AF are more
likely to suffer a thromboembolic event and tend to suffer
worse clinical outcomes poststroke than their male coun-
terparts, it has been noted that the more recent the study of
excess female risk for thromboembolic events in AF, the
lower this risk appears to be. In the 2003 Framingham
study,13 the risk for women was increased by 90%; by 80%
in the 2007 Euro Heart Survey15; by 50% in the 2005
ATRIA study36; and by 47% in the large Swedish cohort
study22 in 2012. This is reﬂected in the 2012 ESC guidelines
stating that women aged <65 years with lone AF are
considered low risk and thus, no antithrombotic therapy
should be considered. A female patient with AF can have
0 or 2 to 9 points with the CHA2DS2-VASc scoring system,
as female gender is currently only recognized as a risk factor
in the presence of at least one other risk factor.
Reasons Why Stroke Risk in Women May Be
Increased: Many reasons have been hypothesized to
account for the apparent increased thrombogenicity inwomen
Table 1
Observational studies addressing gender
Publication
(year)
Cohort Total n # of
females
%
female
Age (years) Stroke (%) Relative Risk
Males Females p Value Males Females p Value Females p Value
Inoue (2000)12* Japan 740 234 31.6 56 † NR NR NR NR RR 0.5 M 0.0291
Humphries (2001)5* CARAF (Canada) 1097 339 30.9 60.50.6 65.40.7 <0.001 6.5z 7.8z NS NR NR
Wang (2003)13 Framingham Heart Study
(USA)
705 336 47.7 75 † NR NR NR NR HR 1.92 M NR
Friberg (2004)14 Copenhagen City Heart
Study
276 110 39.9 678.4 696.8 NR 7.8 20 NR HR 2.6 M NR
4.7 yearsx
Dagres (2007)15* Euro Heart Survey on AF 5333 2249 42.2 6413 7012 <0.001 1.2 2.2 0.011 OR 1.83 M 0.019 M
1 yearx
Poli (2009)16* University of Florence
(Italy)
780 275 35.3 74 76 <0.001 1.2{ 2.43{ 0.042 HR 2.3 M <0.01
Ruigomez (2009)17* UK General Practice
Research
831 426 51.3 61.2% subjects aged 70† NR NR NR NR RR 1.0 M NS
Lin (2011)18 Taiwan NHI research
database
7920 3633 45.9 63.3% subjects aged 65† NR NR NR NR OR 0.942 U 0.512 U
Oleson (2011)19 Denmark national register 73538 37651 51.2 59.7% subjects aged 75† NR NR NR NR HR 1.6 M 0.04 M
van Staa (2011)20 United Kingdom 79844 39704 49.7 73.3 † NR 1.2 1.9 NR RR 1.05 M NS
4 yearsx
Chao (2012)21* Taiwan NHI research
database
829 320 38.6 45.4  12 † 1 1.6 4.4 0.014 HR 2.48 M 0.042 M
57.4  35.7
monthsx
Friberg (2012)22 Sweden 100802 50667 50.3 74.7 80.9 NR 4.2k 6.2k <0.0001 HR 1.47 U; 1.18 M <0.001
Mikkelsen (2012)23 Denmark 87202 44744 51.3 71 78.2 <0.0001 3.7{ 5.43{ NR HR 1.04 M NR
Potpara (2012)24 Belgrade AF Study
(Serbia)
862 315 46.5 49.6 56.7 <0.001 6.9 7 0.579 HR 1.11 U 0.579 U
10.16.1
yearsx
Tsadok (2012)25* Quebec (Canada) 83513 44115 52.8 77.2 80.2 NR 4.3 5.8 <0.001 HR 1.14 M <0.001 M
30, 90, 365
daysx
Bosch (2013)26* Germany 2742 1021 37.2 67.59.9 71.29.3 <0.001 3.4 3.6 0.74 NR NR
6, 12 monthsx
Disertori (2013)27* GISSI-AF subset 1234 487 39.5 66.75 paroxysmal AF;
68.78 persistent AF†
NR 3 9 NR NR NR
1 yearx
Guo (2013)28 Chinese PLA General
Hospital
1034 281 27.2 78 71 <0.0001 8.1 6.05 0.267 NR NR
1.9 yearsx
Poli (2013)29* EPICA study (Italy) 3015 1654 54.9 82.6** 83.1** 0.001 1.3{x 1.6{ 0.25 OR 1.2 U 0.3 U
Salam (2013)30* Hamad General Hospital
(Qatar)
3849 1417 36.8 54.5  15.7 59  15 0.001 0.4 0.4 0.8 NR NR
20 yearsx
Aakre (2014)31 Olmsted County,
Minnesota (USA)
2720 1320 48.5 73.3314.57 † NR NR NR NR HR 1.45 M 0.0015 M
Inoue (2014)32 J-RHYTHM 7406 2165 29.2 6910 739 <0.001 1.8 1.6 0.576 OR 0.89 U 0.576 U
2 yearsx
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1024 The American Journal of Cardiology (www.ajconline.org)with AF. Differences in baseline patient characteristics
involving AF presentation, medical co-morbidities, and
stroke risk proﬁles may contribute to the increased stroke
risk in women.55 Age is a well-known risk factor for stroke,
and female patients in most studies were older, in the large
Swedish cohort study, the mean age was 6 years higher in
women than men,22 and it has been argued that this could
account for the increase in thromboembolic risk. One study
reported signiﬁcantly larger left atrial dimensions in women
(44.0  6.5 vs 40.6  6.3, p ¼ 0.0026); however, another
study found no difference in atrial size.16 Women with AF
are also more likely to have preexisting
hypertension,5,15,22,25,37,41 valvular heart disease,3,15 and
heart failure with preserved left ventricular function,15 but
less likely to have coronary artery disease than men.15,36
Women are more likely to have preexisting thyroid
abnormalities,15,49 which may also contribute to their
increased thromboembolic risk. A 2010 study found that
hyperthyroidism contributed a 1.44-time greater risk of
ischemic stroke (95% CI 1.01 to 2.12; p ¼ 0.038), after
adjusting for age, gender, and AF, among other factors.56 In
addition to these co-morbidities, in particular, women with
AF are more likely than their male counterparts to have a
history of previous stroke—the strongest independent
predictor for stroke.22,25,36 However, many of the larger
cohort studies adjusted for these co-morbidities and yet still
found that women have a higher stroke risk.46
Other reasons suggested for the increased stroke risk in
women include the possibility that women may have
increased hypercoagulable qualities, such as endothelial
dysfunction and prothrombotic factors, including elevated
ﬁbrinogen levels,57 von Willebrand factor,58,59 and
increased platelet activation.55,60,61 In addition, hormone
replacement therapy (HRT) has been posited as a potential
reason for the difference in thrombogenicity. SPAF III re-
ported that estrogen hormone replacement therapy was
independently associated with signiﬁcantly higher rates of
ischemic stroke in women with AF,38 whereas ATRIA and
the Stroke Prevention using an Oral Thrombin Inhibitor
(SPORTIF) study did not ﬁnd a signiﬁcant association.36,37
However, the mixed evidence and low percentages of
women using estrogen HRT in these studies suggest that this
may not be the sole factor for increased stroke risk.
Clinical Relevance of Gender Differences in
Thromboembolic Risk: Compared with men, women tend
to be more symptomatic—experiencing longer episodes,
more frequent recurrences, and faster ventricular response
rates during AF.5,6,41,49,62 Women with AF also tend to have
lower quality of life15,41,62,63 and are older than men at the
time of presentation.5,9,15,25,30,37,41,64,65 In addition to these
clinical differences in presentation between men and
women with AF, there are also disparities in the medical
management of these patients. These gender differences in
the medical management of AF may increase stroke risk
differences in men and women. In patients with atypical or
no AF symptoms in the Euro Heart Survey on Atrial
Fibrillation, treatment was more conservative in women,
with signiﬁcantly less utilization of rhythm-control
strategies than in men.15 In a Serbian study, men were more
likely to undergo electrocardioversion or to be prescribed
Table 2
Randomized controlled trials (RCTs) addressing gender
Publication
(year)
Cohort Total
n
# of
females
%
female
Age (years) Stroke (%) Relative Risk
Males Females p Value Males Females p
Value
Females p Value
Hart (1999)38 SPAF I-III 1853 514 27.7 68 71 NR 2.1* 4.4* NR RR 1.8 U; 1.6 M 0.03 U; 0.01 M
Fang (2005)36 ATRIA cohort 13559 5795 42.7 NR NR NR 1.8* 3.5* NR RR 1.6 M NR
Rienstra (2005)41 † RACE substudy 522 192 36.8 679 718 <0.001 6.7 6.8 NS NR NR
2.3 yearsz
Gomberg-
Maitland (2006)37
SPORTIF
III and V
7329 2257 30.8 69.89 73.48 <0.0001 1.44* 2.08* 0.016 HR 1.44
U; 1.27 M
0.0161
U; 0.16 M
Sullivan (2012)39 AFFIRM
substudy
4060 1594 39.3 68.38.3 71.37.5 <0.0001 3 5 0.002 OR 1.6 M 0.002 M
2000 daysz
All studies recruited patients with nonvalvular AF.
AFFIRM ¼ Atrial Fibrillation Follow-up Investigation of Rhythm Management; HR ¼ hazard ratio; M ¼ multivariate analysis; OR ¼ odds ratio; RR ¼
relative risk; U ¼ univariate analysis.
* Percentage per year.
† Additional therapies examined calcium channel blockers, b blockers, electrocardioversions, antiarrhythmic drugs.
zMean follow-up duration provided for studies with stroke percentage incidence reported during study follow-up.
Table 3
NOAC drug studies addressing gender
Publication
(year)
Cohort Arm of
Study
Total n # of
females
%
female
Age (years) Stroke (%)
Males Females p Value Males Females p Value
Connolly (2009)42 RE-LY Dabigatran 110 mg 6015 2150 35.7 71.48.6 * NR 1.35† 1.86† 0.96
Dabigatran 150 mg 6076 2236 36.8 71.58.8 * NR 1.10† 1.14† 0.24
Warfarin 6022 2213 36.7 71.68.6 * NR 1.49† 2.03† NR
Connolly (2011)43 AVERROES Apixaban 2808 1148 40.9 68.6 71.4 NR 1.4† 1.9† 0.42
Aspirin 2791 1174 42.1 68.8 71.8 NR 2.7† 4.9† 0.42
Granger (2011)44 ARISTOTLE Apixaban 9120 3234 35.5 70z * NR 1.2† 1.4† 0.6
Warfarin 9081 3182 35 70z * NR 1.5† 1.8† 0.6
Patel (2011)45 ROCKET-AF Rivaroxaban 7131 2831 39.7 73z * NR NR NR NR
Warfarin 7133 2832 39.7 73z * NR 2.02x 2.67x <0.001
All studies recruited patients with nonvalvular AF.
ARISTOTLE ¼ Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF; AVERROES ¼ Apixaban Versus Acetylsalicylic Acid to
Prevent Stroke in AF Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; RE-LY ¼ Randomized Evaluation of Long-Term
Anticoagulation Therapy; ROCKET-AF ¼ Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in AF.
* Gender-speciﬁc mean age not provided.
† P per year.
zMedian age.
x Events/100 patient-years.
Review/Gender Differences of Stroke in AF 1025OAC (both p<0.001), whereaswomenweremore likely to be
prescribed b blockers and calcium channel blockers (both p
<0.01).24
Similarly, a recent study in France found that women over
the age of 75 years were 1/3 less likely to be treated with
systemic anticoagulation than men of similar age.66 The Ca-
nadian Registry of Atrial Fibrillation (CARAF) study found
that older women were half as likely to receive warfarin and
twice as likely to receive aspirin compared with older men.5
When women are prescribed systemic anticoagulation, differ-
ences may also exist in terms of the quality of anticoagulation.
According to the Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study, women with AF on
warfarin spent less time in therapeutic range (TTR) than men
(40  0.7% vs 37  0.5%, p ¼ 0.0001), with more time spentbelow TTR (29  0.7% vs 26  0.5%, p ¼ 0.0002).39 Dif-
ferences in TTR, an important predictor of thromboembolic
outcomes in AF, could indicate lower quality of warfarin
anticoagulation in females.
The lower rates of anticoagulation prescription for female
patientsmay be related to the perception of increased bleeding
risk in women compared with men. The CARAF study re-
ported a 3.35-fold increased risk of major bleeding in women
on warfarin compared with men on warfarin.5 The SPORTIF
trials found no difference in major bleeding rates (p¼ 0.766),
but women experienced more overall bleeding (p <0.001)
and were more prone to anticoagulant-related bleeding.37
However, they also reported that the higher rate of thrombo-
embolism inwomenwas related tomore frequent interruption
of anticoagulant therapy. The ATRIA study found that the
Table 4
Recent evolution of risk stratiﬁcation models
Year Risk Stratiﬁcation Model Gender as Risk Factor
2001 CHADS2 Female gender not included
2003 Framingham stroke risk
score
Female gender incorporated
as risk factor
2006 ACC/AHA/ESC
guidelines
Recognized female gender as
one of the “less validated or
weaker risk factors”
2009 CHA2DS2-VASc Female gender incorporated
as risk factor
2010/2012 ESC guidelines Upgraded female gender from
a “less validated or weaker
risk factor” to a “clinically
relevant non-major risk
factor”
2012 Canadian Cardiovascular
Society guidelines
update
Recommended use of
CHADS2 in 2010. In 2012,
guidelines updated to
consider CHA2DS2-VASc
if CHADS2 ¼ 0 and
addressed single point for
female
ACC/AHA/ESC ¼ American College of Cardiology/American Heart
Association/European Society of Cardiology.
1026 The American Journal of Cardiology (www.ajconline.org)reduction in rates of thromboembolism with warfarin was
larger in women than in men (p ¼ 0.01 for interaction of
gender and warfarin) and found no gender differences in rates
of major hemorrhage while on warfarin.36 The Rate Control
versus Electrical Cardioversion (RACE) study reported a
lower incidence of bleeding in women compared with men.41
SPAF reported that women derived greater beneﬁt from
anticoagulation than did men.67 Thus, these gender differ-
ences become important because althoughwomenmay derive
more beneﬁt from systemic anticoagulation than their male
counterparts, they may be less likely to receive systemic
anticoagulation and when they are anticoagulated, the quality
of anticoagulation may be lower.
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